Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
